35 results about "Sodium fusidate" patented technology

A mixed liposome pharmaceutical formulation with multilamellar vesicles, comprises a proteinic pharmaceutical agent, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt. / wt. %, at least one membrane-mimetic amphiphile and at least one phospholipid. The membrane-mimetic amphiphile is hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, lauramidopropyl betain, lauramide monoisopropanolamide, sodium cocoamphopropionate, bishydroxypropyl dihydroxypropyl stearammonium chloride, polyoxyethylene dihydroxypropyl stearammonium chloride, dioctadecyldimethylammonium chloride, sulphosuccinates, stearamide DEA, gamma-linoleic acid, borage oil, evening of primrose oil, monoolein, sodium tauro dihydro fusidate, fusidic acid, alkali metal isostearyl lactylates, alkaline earth metal isostearyl lactylates, panthenyl triacetate, cocamidopropyl phosphatidyl PG-diammonium chloride, stearamidopropyl phosphatidyl PG-diammonium chloride, borage amidopropyl phosphatidyl PG-diammonium chloride, borage amidopropyl phosphatidylcholine, polysiloxy pyrrolidone linoleyl phospholipid, trihydroxy-oxo-cholanylglycine and alkali metal salts thereof, and octylphenoxypolythoxyethanol, polydecanol X-lauryl ether, polydecanol X-oleyl ether, wherein X is from 9 to 20, or combinations thereof. The phospholipid is phospolipid GLA, phosphatidyl serine, phosphatidylethanolamine, inositolphosphatides, dioleoylphosphatidylethanolamine, sphingomyelin, ceramides, cephalin, triolein, lecithin, saturated lecithin and lysolecithin, or a combination thereof. The amount of each membrane mimetic amphiphile and phospholipid is present 1 to 10 wt. / wt. % of the total formulation, and the total concentration of membrane mimetic amphiphiles and phospholipids is less than 50 wt. / wt. % of the formulation.

The invention relates to a sodium fusidate combination and the preparation method of freeze dried formulation. Weight ratio of the sodium fusidate, the excipient and the stabilizing agent / pH regulator in the sodium fusidate combination is 25 to 100 : 2 to 100 : 1 to 50, wherein, preferred excipient is glucose and / or mannitol; the stabilizing agent / pH regulator is one from arginine, ethylene diamine tetraacetic acid disodium and EDTA calcium disodium or the mixture. The preparation method is characterized in that: water is used as solvent; the sodium fusidate, the excipient and the stabilizing agent / pH regulator are made into clear and transparent solution before filtered and subpacked, thereby producing freeze dried formulation being suitable for requirement of injection through drying by sublimation, wherein, pH value of the formulation is 7.5 to 9.0 and the formulation of each unit dose comprises 125 to 500mg sodium fusidate. The sodium fusidate combination and the preparation method of freeze dried formulation have the advantages of good stability, convenient use, improvement of drugs tolerance upon patients and simple medical operation, strong practicability, simple technology and good stability of finished product.

The invention provides a sodium fusidate crystallization method which comprises the following steps: a, preparing a sodium fusidate solution by taking a acetone water solution as solvent; b, heating the sodium fusidate solution, feeding acetone while stirring, reducing the feeding rate when the sodium fusidate solution is turbid, and standing for crystallization after the feeding operation is finished; and performing solid-liquid separation, leaching the obtained solids with acetone, and then drying to obtain sodium fusidate crystals. According to the invention, the method is simple to operate and low in cost; and the sodium fusidate crystals prepared by the method are stable in crystal form and favorable in flowability.

The present invention is directed to a medicinal composition for treating bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises a) a biopolymer in the form of Chitosan, b) an Active Pharmaceutical Ingredient (API), in the form of fusidic, c) a cream base, and d) water. The invention also discloses a process to make the medicinal cream in which Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, by converting it into Fusidic acid under oxygen-free environment created using inert gas, preferably nitrogen. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid and found to be surprisingly superior for use against skin infections with allergy & itching, & wounds on human skin than alternative creams currently available.

The invention relates to the field of pharmaceutical preparation, and particularly discloses sodium fusidate freeze-dried powder injection and a preparation method thereof. The sodium fusidate freeze-dried powder injection disclosed by the invention is prepared from sodium fusidate, dimercaprol dimercaptopropanol, erythorbic acid, cysteine hydrochloride, phenylalanine, arginine and injection water in a freeze-drying manner. Preferably, the arginine, the dimercaprol dimercaptopropanol, erythorbic acid, cysteine hydrochloride and phenylalanine are taken as auxiliary materials of the sodium fusidate freeze-dried powder injection; stable performance of the sodium fusidate freeze-dried powder injection is improved by synergistic effect; the content of related substances is reduced; the characters of a product are maintained in a normal requirement; and safe use and long-term storage of clinical drugs are facilitated.

The invention provides a freeze-dried sodium fusidate powder for injection with double auxiliary materials, relates to the field of pharmaceutical preparations and preparation methods, and mainly solves the problem of excipients in the production formula of sodium fusidate freeze-dried powder for injection in the prior art The disadvantages of long freeze-drying time during production, high drying temperature, high energy consumption, and low pass rate of finished product clarity and solution color. The sodium fusidate freeze-dried powder for injection uses double excipients, the excipients include mannitol and hydroxyethyl starch 130 / 0.4, the main drug is sodium fusidate, and the weight ratio of the main drug sodium fusidate to the auxiliary materials 100:100‑100:120, the weight ratio between mannitol and hydroxyethyl starch 130 / 0.4 is 100:70‑100:90. The above main drug and auxiliary materials are used to prepare sodium fusidate freeze-dried powder for injection. The sodium fusidate freeze-dried powder for injection provided by the invention is stable in quality, safe and effective, simple in production process, short in freeze-drying time during production, low in drying temperature, low in energy consumption, high in the clarity of the finished product and high pass rate of solution color .